Global healthcare company Roche is confident of growth in emerging markets despite the financial turmoil in developing economies, the chief executive told CNBC.
"We see continuing strong growth in emerging markets actually, we've seen double-digit growth in markets like China and other important developing countries," Severin Schwan, chief executive of Roche told CNBC Europe's "Squawk Box" on Thursday.
"And penetration with our medicines is still relatively low in those markets so I predict that we'll have continued strong demand for our products."
On Thursday, the Swiss firm reported a 3 percent rise in 2013 sales, just below what analysts forecast in a Reuters poll.
Group sales for the year came in at 46.78 billion Swiss francs ($52.17 billion) on Thursday. Sales growth was strongest in the United States (up 10 percent) and emerging markets (up 12 percent), which grew faster than Europe (up 2 percent) and Japan (up 2 percent), the group said.
Shares of the company were trading down 1.4 percent on Thursday morning.